Form 4: Director James Mulay Executes CG Oncology Stock Sale

Director James Mulay exercised options to acquire 15,600 shares of CG Oncology and subsequently sold them under a 10b5-1 plan.

Summary

• Director James Mulay exercised stock options for 15,600 shares of CG Oncology common stock at a strike price of $36.63.
• Immediately following the exercise, the director sold the entire block of 15,600 shares at a weighted average price of $73.01.
• The transactions were executed on April 17, 2026, pursuant to a Rule 10b5-1 trading plan adopted on June 6, 2025.
• Following these transactions, the director holds zero shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while the director sold their entire stake, the transaction was executed via a pre-arranged 10b5-1 plan, which is a standard mechanism for insider liquidity.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
• The director realized a significant gain on the exercise of options, reflecting the appreciation of the stock price from the $36.63 strike price to the $73.01 sale price.

Negatives

• The director has liquidated their entire direct holding of common stock following this transaction.

Risks

• The sale of shares by an insider may be perceived by some market participants as a lack of long-term confidence in the stock price, despite the pre-planned nature of the sale.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for corporate executives and directors to manage personal liquidity and diversify portfolios without triggering concerns regarding material non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to conduct orderly divestments.
• The transaction volume is consistent with typical director-level equity compensation management.

Stakeholder Impact

• Shareholders should note the reduction in direct ownership by a director, though the pre-planned nature mitigates concerns regarding insider sentiment.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

CG Oncology, CGON, Insider Trading, Form 4, Stock Options, Rule 10b5-1